ANI Pharma Files 8-K on Financial Results & Reg FD Disclosure

Ticker: ANIP · Form: 8-K · Filed: Feb 8, 2024 · CIK: 1023024

Ani Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyAni Pharmaceuticals Inc (ANIP)
Form Type8-K
Filed DateFeb 8, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-results, regulation-fd, corporate-filing

TL;DR

**ANI Pharma just dropped an 8-K about financial results, watch for the details!**

AI Summary

ANI Pharmaceuticals, Inc. filed an 8-K on February 8, 2024, to disclose information under Item 2.02, "Results of Operations and Financial Condition," and Item 7.01, "Regulation FD Disclosure." This filing indicates that the company is likely releasing or has just released financial results or other material non-public information. For investors, this matters because it signals an upcoming or recent announcement that could impact the company's stock price, making it crucial to review the specific details of the financial condition and operations that were disclosed.

Why It Matters

This filing signals that ANI Pharmaceuticals is disclosing important financial information, which could directly influence investor perception and the company's stock valuation.

Risk Assessment

Risk Level: medium — The risk level is medium because the filing itself doesn't contain the financial results, but signals their disclosure, creating uncertainty until the actual numbers are known.

Analyst Insight

A smart investor would immediately look for the accompanying press release or other disclosures referenced by this 8-K to understand the specific financial results and operational updates, as these will directly impact the stock's valuation.

Key Players & Entities

  • ANI PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
  • February 8, 2024 (date) — Date of Earliest Event Reported
  • Delaware (company) — State of incorporation for ANI Pharmaceuticals, Inc.
  • 001-31812 (company) — Commission File Number for ANI Pharmaceuticals, Inc.
  • 58-2301143 (company) — I.R.S. Employer Identification No. for ANI Pharmaceuticals, Inc.
  • 210 Main Street West Baudette, Minnesota 56623 (company) — Address of principal executive offices for ANI Pharmaceuticals, Inc.
  • (218) 634-3500 (company) — Registrant's telephone number for ANI Pharmaceuticals, Inc.
  • Common Stock (company) — Title of each class of securities registered
  • ANIP (company) — Trading Symbol for ANI Pharmaceuticals, Inc. Common Stock
  • Nasdaq Stock Market (company) — Name of each exchange on which ANI Pharmaceuticals, Inc. Common Stock is registered

FAQ

What is the purpose of ANI Pharmaceuticals, Inc.'s 8-K filing on February 8, 2024?

The 8-K filing by ANI Pharmaceuticals, Inc. on February 8, 2024, is to report information under Item 2.02, "Results of Operations and Financial Condition," and Item 7.01, "Regulation FD Disclosure."

What is the trading symbol and exchange for ANI Pharmaceuticals, Inc.'s common stock?

The common stock of ANI Pharmaceuticals, Inc. trades under the symbol ANIP on the Nasdaq Stock Market.

Where are ANI Pharmaceuticals, Inc.'s principal executive offices located?

ANI Pharmaceuticals, Inc.'s principal executive offices are located at 210 Main Street West, Baudette, Minnesota 56623.

What is the state of incorporation for ANI Pharmaceuticals, Inc.?

ANI Pharmaceuticals, Inc. is incorporated in Delaware.

Does this 8-K filing contain the actual financial results?

No, this 8-K filing indicates that information regarding "Results of Operations and Financial Condition" and "Regulation FD Disclosure" is being provided, but the filing itself does not contain the detailed financial results. It serves as a notification of such disclosure.

Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-02-08 08:00:22

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On February 8, 2024, Nikhil Lalwani, President & CEO, and other members of the senior leadership team of ANI Pharmaceuticals, Inc. will present at the Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference in New York City. A copy of the presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*

01

Item 7.01 Regulation FD Disclosure The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*

01 Exhibits

Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated February 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 8, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.